News

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted…
Read More...

JSR Life Sciences Companies Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome…
Read More...

Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development, LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’…
Read More...

American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced an…
Read More...

AstraZeneca announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for…
Read More...

BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company announced a…
Read More...

Celltrion and Lonza announced a contract manufacturing agreement to produce drug substance for Remsima, a biosimilar approved by the EMA and the FDA for a number of autoimmune diseases…
Read More...

Allergan plc announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula…
Read More...

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The…
Read More...

Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has closed a £100 million Series B financing led by incoming U.S.…
Read More...

Cidara Therapeutics, Inc. and Mundipharma announced that they have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology…
Read More...

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian company focused on innovative…
Read More...

Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, announced that it has licensed proprietary…
Read More...

Roche announced that the phase III MINISTONE-2 study showed that one-dose Xofluza (baloxavir marboxil) was a well-tolerated and effective potential treatment for flu in otherwise…
Read More...

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with…
Read More...

BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced completion of construction of a new state-of-the-art manufacturing facility. The new…
Read More...

LabCorp announced that its Covance Drug Development business has launched a laboratory solution within its functional service provider (FSPx) offering. Covance has been offering FSP…
Read More...

Novartis announced full results from its global Phase III PARAGON-HF study, investigating the efficacy and safety of Entresto (sacubitril/valsartan) versus the active comparator…
Read More...